{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:36:15Z","timestamp":1788201375955,"version":"build-2803163510"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Between 1970 and 1991, when viral inhibition reduced the risk, people with a bleeding disorder in the United Kingdom had their missing clotting factors replaced with plasma products derived from donated plasma at risk of infection. We analyzed longer-term survival of people with bleeding disorders exposed to plasma products.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The National Haemophilia Database documents people with bleeding disorders registered, treated before, and alive on 1 January 1992. We estimated all-cause mortality proportional hazard ratios for exposure groups (Human immunodeficiency virus (HIV)\/Hepatitis C virus (HCV) coinfected, HCV-diagnosed, and HCV-status unknown) versus HCV antibody negative, within distinct epochs: 1992\u20131999; 2000\u20132009; 2010\u20132019. We estimated years of life lost by epoch and exposure group versus UK general population lifetables or via parametric survival models compared with people with bleeding disorders negative or unknown for HCV antibodies. Models were adjusted for sex, age band at 1 January 1992, bleeding disorder, and severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 6282 people with bleeding disorders who met inclusion criteria, 15% were HIV\/HCV coinfected, 32% HCV antibody positive, and 28% HCV antibody negative. Compared with HCV-negative, those HIV\/HCV coinfected had an all-cause mortality hazard ratio of 4.2 (95% confidence interval: 2.9, 6.0) and HCV+ of 2.2 (1.7, 2.8) in 2010 to 2019. Years of life lost for 2014 to 2019 were 740 (95% confidence interval: 440, 1030) for HCV+ persons and 270 (130, 400) for HIV\/HCV coinfected persons, compared with HCV unknown or negative persons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>People with bleeding disorders in the United Kingdom infected before, but alive at, 1 January 1992, were still at increased risk of death 3 decades postimplementation of HCV screening of blood supplies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ede.0000000000001935","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:00:11Z","timestamp":1765836011000},"page":"237-246","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Longer-term Survival of UK People with Bleeding Disorders Infected by Human Immunodeficiency Virus and\/or Hepatitis C Virus Through Contaminated Blood Transfusions"],"prefix":"10.1097","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9888-1197","authenticated-orcid":false,"given":"Matthew","family":"Gittins","sequence":"first","affiliation":[{"name":"From theCentre for Biostatistics, School of Health Sciences, University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Palmer","sequence":"additional","affiliation":[{"name":"National Haemophilia Database, United Kingdom Haemophilia Centre Doctors Organisation (UKHCDO), Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xiang","sequence":"additional","affiliation":[{"name":"National Haemophilia Database, United Kingdom Haemophilia Centre Doctors Organisation (UKHCDO), Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6690-8586","authenticated-orcid":false,"given":"Pratima","family":"Chowdary","sequence":"additional","affiliation":[{"name":"National Haemophilia Database, United Kingdom Haemophilia Centre Doctors Organisation (UKHCDO), Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6410-1324","authenticated-orcid":false,"given":"Peter","family":"Collins","sequence":"additional","affiliation":[{"name":"Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6378-8382","authenticated-orcid":false,"given":"Sheila M.","family":"Bird","sequence":"additional","affiliation":[{"name":"MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom"},{"name":"College of Medicine & Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom"},{"name":"Department of Mathematics and Statistics, University of Strathclyde, Glasgow, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"R1-20260831","first-page":"e2707","article-title":"Diagnosis and management of haemophilia.","volume":"344","author":"Fijnvandraat","year":"2012","journal-title":"BMJ (Clinical research ed.)"},{"key":"R2-20260831","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/JBM.S389241","article-title":"Von Willebrand disease epidemiology, burden of illness and management: a systematic review.","volume":"14","author":"Du","year":"2023","journal-title":"J Blood Med"},{"key":"R3-20260831","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-2516.2008.01695.x","article-title":"Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors\u2019 Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology.","volume":"14","author":"Keeling","year":"2008","journal-title":"Haemophilia"},{"key":"R4-20260831","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2010.08139.x","article-title":"A United Kingdom Haemophilia Centre Doctors\u2019 Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.","volume":"149","author":"Richards","year":"2010","journal-title":"Br J Haematol"},{"key":"R5-20260831","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12288-012-0209-0","article-title":"The history and evolution of the clinical effectiveness of haemophilia type a treatment: a systematic review.","volume":"30","author":"Castro","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R6-20260831","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood-2005-11-4407","article-title":"Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up.","volume":"108","author":"Arnold","year":"2006","journal-title":"Blood"},{"key":"R7-20260831","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ajh.1050","article-title":"Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States.","volume":"66","author":"Chorba","year":"2001","journal-title":"Am J Hematol"},{"key":"R8-20260831","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1538-7836.2006.01808.x","article-title":"Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study.","volume":"4","author":"Plug","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R9-20260831","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2516.2009.02188.x","article-title":"Mortality and causes of death in Italian persons with haemophilia, 1990\u20132007.","volume":"16","author":"Tagliaferri","year":"2010","journal-title":"Haemophilia"},{"key":"R11-20260831","doi-asserted-by":"crossref","first-page":"823","DOI":"10.7326\/0003-4819-123-11-199512010-00002","article-title":"Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986.","volume":"123","author":"Triemstra","year":"1995","journal-title":"Ann Intern Med"},{"key":"R12-20260831","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1182\/blood.V79.9.2494.2494","article-title":"Changing causes of death in Pennsylvania\u2019s hemophiliacs 1976 to 1991: impact of liver disease and acquired immunodeficiency syndrome.","volume":"79","author":"Eyster","year":"1992","journal-title":"Blood"},{"key":"R13-20260831","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(97)05413-5","article-title":"Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors\u2019 Organisation.","volume":"350","author":"Darby","year":"1997","journal-title":"Lancet"},{"key":"R17-20260831","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/135952201317080661","article-title":"Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.","volume":"6","author":"Bird","year":"2001","journal-title":"J Epidemiol Biostat"},{"key":"R18-20260831","first-page":"267","article-title":"Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 2: preliminary UK estimates of prevalent injection-related hepatitis C carriers, and derivation of progression rates to liver cirrhosis by gender and age at hepatitis C virus infection.","volume":"6","author":"Bird","year":"2001","journal-title":"J Epidemiol Biostat"},{"key":"R19-20260831","doi-asserted-by":"crossref","first-page":"121","DOI":"10.21037\/atm.2018.02.12","article-title":"Time-varying covariates and coefficients in Cox regression models.","volume":"6","author":"Zhang","year":"2018","journal-title":"Ann Transl Med"},{"key":"R20-20260831","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"R26-20260831","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jclinepi.2022.06.012","article-title":"Estimates of years of life lost depended on the method used: tutorial and comparative investigation.","volume":"150","author":"Chudasama","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"R27-20260831","first-page":"2022.01.18.22269472","article-title":"Estimating life expectancy and years of life lost in epidemiological studies: a review of methods using an example from multimorbidity.","author":"Chudasama","year":"2022","journal-title":"medRxiv"},{"key":"R28-20260831","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1016\/S2352-3018(19)30196-1","article-title":"Global, regional, and national incidence, prevalence, and mortality of HIV, 1980\u20132017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017.","volume":"6","author":"Frank","year":"2019","journal-title":"Lancet HIV"},{"key":"R29-20260831","doi-asserted-by":"crossref","first-page":"8922","DOI":"10.1038\/s41598-020-65841-0","article-title":"Trends and causes of mortality in a population-based cohort of HIV-infected adults in Spain: comparison with the general population.","volume":"10","author":"Fontela","year":"2020","journal-title":"Sci Rep"},{"key":"R30-20260831","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.15182","article-title":"Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018.","volume":"19","author":"Hassan","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"4, Supplement","key":"R31-20260831","doi-asserted-by":"crossref","first-page":"S482","DOI":"10.1016\/j.amepre.2009.12.016","article-title":"Burden of Disease Resulting from Hemophilia in the U.S.","volume":"38","author":"Siddiqi","year":"2010","journal-title":"Am J Prev Med"},{"key":"R34-20260831","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.cmi.2016.08.025","article-title":"Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy.","volume":"22","author":"Dustin","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"R35-20260831","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/lt.24973","article-title":"Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States.","volume":"24","author":"Kwong","year":"2018","journal-title":"Liver Transpl"},{"key":"R37-20260831","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios.","volume":"21","author":"Hern\u00e1n","year":"2010","journal-title":"Epidemiology"}],"container-title":["Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/EDE.0000000000001935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:00:42Z","timestamp":1788199242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/EDE.0000000000001935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ede.0000000000001935","relation":{},"ISSN":["1044-3983","1531-5487"],"issn-type":[{"value":"1044-3983","type":"print"},{"value":"1531-5487","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}